From Financial Modeling Prep: 2025-04-22 16:00:00

In the healthcare sector, ResMed Inc. (NYSE:RMD) specializes in medical devices and cloud-based software applications for sleep and respiratory care. With products in 140 countries, ResMed’s average price target increased from $242.71 a year ago to $265 last month, reflecting analyst confidence in the company’s market position and potential.

As ResMed prepares to release its earnings report, analysts have mixed expectations. While Wall Street anticipates earnings growth, some suggest challenges in surpassing expectations. RBC Capital’s cautious yet positive outlook sets a price target of $233 for ResMed, highlighting uncertainties surrounding the upcoming report.

Despite uncertainties, ResMed’s stock saw a 3.8% increase in the last trading session, indicating positive momentum. However, ongoing fluctuations in earnings estimate revisions may impact future analyst sentiment and stock price targets. Investors should closely monitor these developments to gauge ResMed’s performance in the near term.



Read more at Financial Modeling Prep:: ResMed Inc. (NYSE:RMD) Sees Positive Trend in Cons…